VivoSeq
Cardiovascular

Vascular Disease

58

Pipeline Programs↗

9

Active Trials↗

28

Companies Involved↗

Vascular Disease is a moderately active landscape with 58 programs across 28 companies. The most active players are Regenera Pharma Ltd, Viatris Specialty LLC, Eli Lilly. 20 therapies are approved with 19 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

11/100

Mech. Concentration

9/100

Completion Rate

81/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Regenera Pharma Ltd

1 program

Phase 2V

Viatris Specialty LLC

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical9

L-Citrulline

Asklepion Pharmaceuticals, LLC

Praluent

Regeneron

Propofol

Fresenius Kabi Oncology Ltd.

Rosiglitazone

Alnylam Pharmaceuticals

Intravitreal Injection of Conbercept

Sun Yat-sen University

Phase 14

Nicotinamide Riboside

University of Oklahoma

Desirable TEG

Xuanwu Hospital, Beijing

Undesirable TEG

Xuanwu Hospital, Beijing

ACM-1

Sun Yat-sen University

Phase 26

Alirocumab

Regeneron

Bevacizumab

Bio-Thera Solutions

Sildenafil

Viatris Specialty LLC

Riociguat

Bayer

Macitentan

Johnson & Johnson

Phase 319

Ticagrelor

AstraZeneca

Evacetrapib

Eli Lilly

Aspirin

Bayer

Gadopiclenol

Guerbet

Aflibercept

Regeneron

Approved20

Ranolazine

Menarini International Operations Luxembourg SA

Rivaroxaban

Wim Janssens

Clevidipine

Chiesi Farmaceutici S.p.A.

Ambrisentan

Gilead

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Analysis

Modality Breakdown

92%

Small molecule

61 of 66 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody35%Protein / enzyme23%

Small molecule leads; the ring shows all 66 classified programs, each share of the total. Modality classified for 100% of 67 pipeline programs.

Analysis

Trial Status

50

clinical trials

Completed25 · 50%
Unknown status9 · 18%
Recruiting6 · 12%
Terminated5 · 10%
Not yet recruiting3 · 6%
Temporarily not available1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

50 trials

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
Recruiting·TThe University of Texas Health Science Center, Houston·Phase 1·NCT06280482·15 enrolled
Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)
Recruiting·YYonsei University·N/A·NCT06231966·2,462 enrolled
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD)
Recruiting·TTongji Hospital·N/A·NCT06474507·230 enrolled
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Recruiting·JJohns Hopkins University·Phase 2·NCT04797286·30 enrolled
Qishenyiqi Dripping Pill for Coronary Microvascular Disease
Recruiting·QQilu Hospital of Shandong University·Phase 4·NCT06699420·162 enrolled
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
Recruiting·WW.L.Gore & Associates·N/A·NCT06658730·1,500 enrolled
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
Not yet recruiting·GGuerbet·Phase 3·NCT07348640·315 enrolled
Clinical Evaluation of Aromatic Wentong in the Treatment of Coronary Microvascular Disease
Not yet recruiting·—·Phase 4·NCT06901570·528 enrolled
Perspectives and Experience of Patients From Minority Ethic Communities on Advice Provided About Diet and Lifestyle Advice in Management of Their Cardiovascular Disease
Not yet recruiting·UUniversity of Nottingham·N/A·NCT07672054·15 enrolled
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients
Completed·Bayer logoBayer·Phase 3·NCT00395733·83 enrolled
Noninvasive Assessment of Cerebral Oxygenation and Cardiac Function in Patients With Neurovascular Diseases
Completed·National Institute of Mental Health and Neuro Sciences, India·N/A·NCT02991157·25 enrolled
A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT03153111·143 enrolled
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
Completed·RRegenera Pharma Ltd·Phase 2·NCT03462121·83 enrolled
Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study
Completed·VValley Retina Institute·Phase 4·NCT01486238·72 enrolled
Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease
Completed·Eisai logoEisai·Phase 3·NCT00165737·974 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)